SG10201806715TA - Use of inos inhibitors to increase viral yield in culture - Google Patents
Use of inos inhibitors to increase viral yield in cultureInfo
- Publication number
- SG10201806715TA SG10201806715TA SG10201806715TA SG10201806715TA SG10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA SG 10201806715T A SG10201806715T A SG 10201806715TA
- Authority
- SG
- Singapore
- Prior art keywords
- culture
- inos inhibitors
- viral yield
- increase viral
- increase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 2
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 title 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 abstract 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 abstract 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
- 229960000604 valproic acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16651—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE of the Disclosure The use of iNOS inhibitors, including aurintricarboxylic acid, dexamethasone and valproic acid, to increase the yield of a variety of viruses in culture, including recombinant herpesviruses is described. [Figure 1]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750175P | 2013-01-08 | 2013-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201806715TA true SG10201806715TA (en) | 2018-09-27 |
Family
ID=51167323
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201806715TA SG10201806715TA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
| SG10201913130PA SG10201913130PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
| SG11201505333PA SG11201505333PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913130PA SG10201913130PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
| SG11201505333PA SG11201505333PA (en) | 2013-01-08 | 2014-01-07 | Use of inos inhibitors to increase viral yield in culture |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11299715B2 (en) |
| EP (3) | EP3266866B1 (en) |
| JP (2) | JP6534933B2 (en) |
| KR (1) | KR102307279B1 (en) |
| CN (1) | CN105008523B (en) |
| AR (1) | AR094389A1 (en) |
| AU (1) | AU2014205604B2 (en) |
| BR (2) | BR112015016328B1 (en) |
| CA (1) | CA2897444A1 (en) |
| DK (1) | DK2943567T3 (en) |
| ES (1) | ES2651763T3 (en) |
| HK (2) | HK1214840A1 (en) |
| HU (1) | HUE037482T2 (en) |
| IL (1) | IL239824B (en) |
| MX (1) | MX360470B (en) |
| NO (1) | NO3050055T3 (en) |
| RU (1) | RU2676733C2 (en) |
| SG (3) | SG10201806715TA (en) |
| TW (1) | TWI608102B (en) |
| WO (1) | WO2014110053A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017009497A2 (en) | 2014-11-05 | 2018-02-06 | Voyager Therapeutics, Inc. | aadc polynucleotides for the treatment of parkinson's disease |
| BR112017010087A2 (en) | 2014-11-14 | 2018-06-05 | Voyager Therapeutics, Inc. | compositions and methods for treating amyotrophic lateral sclerosis (her) |
| KR20230145206A (en) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | Modulatory polynucleotides |
| EP3230441A4 (en) | 2014-12-12 | 2018-10-03 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| ES2938833T3 (en) | 2016-03-28 | 2023-04-17 | Ultragenyx Pharmaceutical Inc | Adenovirus heat inactivation methods |
| MX2018014154A (en) | 2016-05-18 | 2019-05-06 | Voyager Therapeutics Inc | Modulatory polynucleotides. |
| US11795473B2 (en) | 2016-10-14 | 2023-10-24 | Ultragenyx Pharmaceutical Inc. | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
| WO2018175775A1 (en) | 2017-03-22 | 2018-09-27 | Dimension Therapeutics | Cell culture methods involving hdac inhibitors or rep proteins |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CN110835622B (en) * | 2018-08-16 | 2021-04-27 | 上海药明生物技术有限公司 | Culture medium for regulating lactic acid metabolism of mammalian cells and application thereof |
| KR20220155334A (en) | 2020-03-16 | 2022-11-22 | 울트라제닉스 파마수티컬 인코포레이티드 | Methods for enhancing recombinant adeno-associated virus yield |
| WO2023157976A1 (en) * | 2022-02-21 | 2023-08-24 | 学校法人日本医科大学 | Viral vector producibility enhancer and method for producing viral vector |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| RU2012335C1 (en) * | 1991-07-04 | 1994-05-15 | Уфимский научно-исследовательский институт глазных болезней | Inhibitor of herpes simplex virus |
| ES2197145T3 (en) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | TRANSFER OF GENES MEDIATED BY ADENOVIRUS TO GASTROINTESTINAL. |
| CA2141574C (en) * | 1992-07-31 | 2009-11-24 | David Knipe | Herpesvirus vaccines |
| US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| US6833271B2 (en) | 1996-12-04 | 2004-12-21 | Medi-Cult A/S | Serum-free cell culture media |
| GB9816856D0 (en) * | 1998-08-03 | 1998-09-30 | Univ London | Cell lines for virus growth |
| US6783972B1 (en) * | 1998-09-22 | 2004-08-31 | University Of Florida Research Foundation | Methods for large-scale production of recombinant AAV vectors |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US7091029B2 (en) * | 2002-09-23 | 2006-08-15 | Applied Genetics Technologies Corporation | High titer recombinant AAV production |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| CN100348718C (en) * | 2005-10-18 | 2007-11-14 | 中国人民解放军军事医学科学院生物工程研究所 | Culture medium without animal originating component and serum for HEK293 cell adhesion culture |
| KR101551238B1 (en) * | 2007-06-29 | 2015-09-09 | 한국화학연구원 | Novel hiv reverse transcriptase inhibitors |
-
2014
- 2014-01-07 BR BR112015016328-9A patent/BR112015016328B1/en active IP Right Grant
- 2014-01-07 HU HUE14703459A patent/HUE037482T2/en unknown
- 2014-01-07 EP EP17184746.0A patent/EP3266866B1/en active Active
- 2014-01-07 DK DK14703459.9T patent/DK2943567T3/en active
- 2014-01-07 RU RU2015133205A patent/RU2676733C2/en active
- 2014-01-07 EP EP19160865.2A patent/EP3521420A1/en not_active Withdrawn
- 2014-01-07 AU AU2014205604A patent/AU2014205604B2/en not_active Ceased
- 2014-01-07 BR BR122020002822-0A patent/BR122020002822B1/en active IP Right Grant
- 2014-01-07 MX MX2015008861A patent/MX360470B/en active IP Right Grant
- 2014-01-07 EP EP14703459.9A patent/EP2943567B1/en active Active
- 2014-01-07 ES ES14703459.9T patent/ES2651763T3/en active Active
- 2014-01-07 WO PCT/US2014/010553 patent/WO2014110053A1/en active Application Filing
- 2014-01-07 US US14/758,785 patent/US11299715B2/en active Active
- 2014-01-07 KR KR1020157021175A patent/KR102307279B1/en active IP Right Grant
- 2014-01-07 CA CA2897444A patent/CA2897444A1/en not_active Abandoned
- 2014-01-07 SG SG10201806715TA patent/SG10201806715TA/en unknown
- 2014-01-07 CN CN201480012376.2A patent/CN105008523B/en active Active
- 2014-01-07 SG SG10201913130PA patent/SG10201913130PA/en unknown
- 2014-01-07 SG SG11201505333PA patent/SG11201505333PA/en unknown
- 2014-01-07 TW TW103100466A patent/TWI608102B/en active
- 2014-01-07 JP JP2015551846A patent/JP6534933B2/en active Active
- 2014-01-08 AR ARP140100065A patent/AR094389A1/en unknown
- 2014-09-26 NO NO14781027A patent/NO3050055T3/no unknown
-
2015
- 2015-07-07 IL IL239824A patent/IL239824B/en active IP Right Grant
-
2016
- 2016-03-10 HK HK16102764.2A patent/HK1214840A1/en unknown
-
2018
- 2018-07-10 HK HK18108963.6A patent/HK1249544A1/en unknown
-
2019
- 2019-05-28 JP JP2019098958A patent/JP6837094B2/en active Active
-
2022
- 2022-03-03 US US17/686,245 patent/US20220340883A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201806715TA (en) | Use of inos inhibitors to increase viral yield in culture | |
| MX355428B (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]- acetic acid. | |
| MX2020003096A (en) | Pharmaceutical formulations of a hif hydroxylase inhibitor. | |
| MX2015009037A (en) | Honey nasal rinse. | |
| MX2019004568A (en) | Improved production of fatty acid derivatives. | |
| MX2012009581A (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease. | |
| EP2803657A4 (en) | Crystal form of prostaglandin analogue, and preparation method and use thereof | |
| EP2808318A4 (en) | Crystal form of prostaglandin analogue, and preparation method and use thereof | |
| MX2015014816A (en) | Microrna compounds and methods for modulating mir-122. | |
| PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
| MX365302B (en) | Methods of therapeutic monitoring of phenylacetic acid prodrugs. | |
| IN2014DN07958A (en) | ||
| MD20130073A2 (en) | New crystal form VII of agomelatine, preparation method and use thereof, and pharmaceutical composition containing the same | |
| IN2013MU01431A (en) | ||
| AU2016204276A1 (en) | Methods for producing virus particles with simplified glycosylation of surface proteins | |
| EP3242932A4 (en) | Employing human adipose-derived stem cells to propagate serum-derived hepatitis c virus and use thereof | |
| MX2020002286A (en) | Composition for treating cancer associated with hpv infection. | |
| MY170453A (en) | Etching material | |
| MX2015010763A (en) | H5 proteins of h5n1 influenza virus for use as a medicament. | |
| WO2014115087A3 (en) | A method for the preparation of recombinant human prothrombin and fibrinogen | |
| WO2015066488A3 (en) | Method for producing induced pluripotent stem cells | |
| MX353587B (en) | Pharmaceutical compositions containing ipidacrine and use thereof to treat potency disorders and other sexual activity disorders. | |
| IN2013CH04330A (en) | ||
| IN2013MU03086A (en) | ||
| UA77066U (en) | Method for preparation of anatomical preparations |